AU8929791A - Controlling glutamine/glutamate related neuronal injury - Google Patents

Controlling glutamine/glutamate related neuronal injury

Info

Publication number
AU8929791A
AU8929791A AU89297/91A AU8929791A AU8929791A AU 8929791 A AU8929791 A AU 8929791A AU 89297/91 A AU89297/91 A AU 89297/91A AU 8929791 A AU8929791 A AU 8929791A AU 8929791 A AU8929791 A AU 8929791A
Authority
AU
Australia
Prior art keywords
glutamine
controlling
neuronal injury
related neuronal
glutamate related
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU89297/91A
Inventor
Paul A Rosenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Childrens Medical Center Corp
Original Assignee
Childrens Medical Center Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Medical Center Corp filed Critical Childrens Medical Center Corp
Publication of AU8929791A publication Critical patent/AU8929791A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
AU89297/91A 1990-10-29 1991-10-29 Controlling glutamine/glutamate related neuronal injury Abandoned AU8929791A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/605,528 US5158976A (en) 1990-10-29 1990-10-29 Controlling glutamine/glutamate related neuronal injury
US605528 1996-02-22

Publications (1)

Publication Number Publication Date
AU8929791A true AU8929791A (en) 1992-05-26

Family

ID=24424041

Family Applications (1)

Application Number Title Priority Date Filing Date
AU89297/91A Abandoned AU8929791A (en) 1990-10-29 1991-10-29 Controlling glutamine/glutamate related neuronal injury

Country Status (3)

Country Link
US (1) US5158976A (en)
AU (1) AU8929791A (en)
WO (1) WO1992007562A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824662A (en) * 1996-09-27 1998-10-20 Guilford Pharmaceuticals Inc. Treatment of global and focal ischemia using naaladase inhibitors
US6413948B1 (en) 1996-09-27 2002-07-02 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of effecting a neuronal activity in an animal using naaladase inhibitors

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9118866D0 (en) * 1991-09-04 1991-10-23 Unilever Plc Cosmetic composition
FR2689520B1 (en) * 1992-04-03 1996-07-19 Bio Merieux METHOD AND CULTURE MEDIUM FOR OBTAINING CELLS INFECTED WITH A VIRUS ASSOCIATED WITH MULTIPLE SCLEROSIS.
FR2689521B1 (en) * 1992-04-03 1996-07-19 Bio Merieux PROCESS FOR OBTAINING AND MAINTAINING A SUSTAINABLE CELL CULTURE INFECTED WITH A VIRUS ASSOCIATED WITH MULTIPLE SCLEROSIS, AND BIOLOGICALS DERIVED FROM SAID CULTURE.
WO1994027602A1 (en) * 1993-06-01 1994-12-08 Cortex Pharmaceuticals, Inc. Use of metabotropic receptor agonists in progressive neurodegenerative deseases
CA2141907A1 (en) * 1994-02-04 1995-08-05 Herve Perron Virus msrvl and pathogen agent and/or msrv2 associated with multiple sclerosis, their nucleic constituants and their applications
FR2716198B1 (en) * 1994-02-15 1996-04-19 Bio Merieux Cytotoxic factor as associated with multiple sclerosis, its detection and quantification.
FR2737500B1 (en) * 1995-08-03 1997-08-29 Bio Merieux VIRAL MATERIAL AND NUCLEOTIDE FRAGMENTS ASSOCIATED WITH MULTIPLE SCLEROSIS, FOR DIAGNOSIS, PROPHYLACTICS AND THERAPEUTICS
US6017903A (en) 1996-09-27 2000-01-25 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors
EP0942987B1 (en) 1996-11-26 2009-08-19 Bio Merieux Viral material and nucleotide fragments associated with multiple sclerosis, for diagnostic, prophylactic and therapeutic purposes
US6310093B1 (en) 1997-08-29 2001-10-30 Elan Pharmaceuticals, Inc. Method of preventing neuronal death
FR2796552A1 (en) * 1999-07-21 2001-01-26 Centre Nat Rech Scient NOVEL USE OF BETA-NAPHTOQUINONE DERIVATIVES AND THEIR SALTS FOR THE MANUFACTURE OF MEDICINES HAVING AN INHIBITOR EFFECT ON THE RELEASE OF GLUTAMATE IN THE BRAIN
US6451828B1 (en) 2000-08-10 2002-09-17 Elan Pharmaceuticals, Inc. Selective inhibition of glutaminase by bis-thiadiazoles
US6984375B2 (en) * 2001-08-03 2006-01-10 Allergan, Inc. Nuclei density and nuclei area methods for determining effects of a botulinum toxin on muscles
EP1434576A4 (en) * 2001-09-13 2006-03-29 Kenneth E Miller Method of alleviating pain
US7504231B2 (en) * 2001-09-13 2009-03-17 The Board Of Regents Of The University Of Oklahoma Method of alleviating chronic pain via peripheral inhibition of neurotransmitter synthesis
US20090304712A1 (en) * 2006-02-02 2009-12-10 National University Corporation Nagoya University Neuronal Cell Death Inhibitor and Screening Method
US20110059168A1 (en) * 2009-09-09 2011-03-10 Ang Sam Method for correcting intestinal glutamine synthetase deficiency
WO2016201307A1 (en) * 2015-06-12 2016-12-15 The United State of America, as represented by the Secretary, Dept. of Health and Human Services Glutamine antagonists for use in treating cerebral edema and cerebral malaria
DK3692015T3 (en) * 2017-10-06 2022-11-21 Univ Johns Hopkins PREVIOUSLY UNKNOWN GLUTAMINE ANTAGONISTS AND USES THEREOF
KR20230070702A (en) * 2021-11-15 2023-05-23 한국해양과학기술원 Novel Ramalin Derivatives and Their Uses for Prevention or Treatment of Degenerative Brain Diseases

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824662A (en) * 1996-09-27 1998-10-20 Guilford Pharmaceuticals Inc. Treatment of global and focal ischemia using naaladase inhibitors
US5985855A (en) * 1996-09-27 1999-11-16 Guilford Pharmaceuticals Inc. Treatment of global and focal ischemia using NAALADase inhibitors
US6004946A (en) * 1996-09-27 1999-12-21 Guilford Pharmaceuticals Inc. Treatment of global and focal ischemia using naaladase inhibitors
US6413948B1 (en) 1996-09-27 2002-07-02 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of effecting a neuronal activity in an animal using naaladase inhibitors

Also Published As

Publication number Publication date
US5158976A (en) 1992-10-27
WO1992007562A1 (en) 1992-05-14

Similar Documents

Publication Publication Date Title
AU8929791A (en) Controlling glutamine/glutamate related neuronal injury
GB2280462B (en) Setting apparatus
AU7852291A (en) Lockable quick-release mechanism
AU6134494A (en) Adjustable dumbbell
EP0468340A3 (en) Eye directed controller
AU6778894A (en) Adjustable comb
EP0537352A4 (en) Nc-machining controller
GB9321602D0 (en) Controller
GB9317981D0 (en) Adjustable fastening arrangement
AU635477B2 (en) Ignition controlling device
AU646273B2 (en) Acetamide derivatives
AU5711494A (en) Adjustable aperture apparatus
AU7325391A (en) Adjustable hurdle
AU628720B2 (en) Control apparatus
GB9320676D0 (en) Treatment fo wood
GB9210313D0 (en) Adjustable prambrella
GB9414828D0 (en) Adjustment device
HU9301651D0 (en) Pyridyl-1,2,5-oxadiazole-carbonamide-2-oxide derivatives
AU7976491A (en) Special effects controller
AU3084992A (en) 1,4-dihydropyridines for use in the treatment of dermatosis
GB9108528D0 (en) Controller
GB9723635D0 (en) Adjustment device
AU7608091A (en) Adjustable lecturn
AU662249B2 (en) Adjustable pulley
HU9402902D0 (en) 1,2-dihydro-2-oxo-3-methyl-sulfonyl-aminomethyl-pyridine derivatives